368 related articles for article (PubMed ID: 23784932)
1. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse.
Reinartz S; Schumann T; Finkernagel F; Wortmann A; Jansen JM; Meissner W; Krause M; Schwörer AM; Wagner U; Müller-Brüsselbach S; Müller R
Int J Cancer; 2014 Jan; 134(1):32-42. PubMed ID: 23784932
[TBL] [Abstract][Full Text] [Related]
2. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.
Kawamura K; Komohara Y; Takaishi K; Katabuchi H; Takeya M
Pathol Int; 2009 May; 59(5):300-5. PubMed ID: 19432671
[TBL] [Abstract][Full Text] [Related]
3. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer.
Lan C; Huang X; Lin S; Huang H; Cai Q; Wan T; Lu J; Liu J
Technol Cancer Res Treat; 2013 Jun; 12(3):259-67. PubMed ID: 23289476
[TBL] [Abstract][Full Text] [Related]
4. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.
Yang L; Wang F; Wang L; Huang L; Wang J; Zhang B; Zhang Y
Oncotarget; 2015 Apr; 6(12):10592-603. PubMed ID: 25871392
[TBL] [Abstract][Full Text] [Related]
5. Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.
Adhikary T; Wortmann A; Finkernagel F; Lieber S; Nist A; Stiewe T; Wagner U; Müller-Brüsselbach S; Reinartz S; Müller R
BMC Genomics; 2017 Mar; 18(1):243. PubMed ID: 28327095
[TBL] [Abstract][Full Text] [Related]
6. High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time.
He YF; Zhang MY; Wu X; Sun XJ; Xu T; He QZ; Di W
PLoS One; 2013; 8(12):e79769. PubMed ID: 24324582
[TBL] [Abstract][Full Text] [Related]
7. Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment.
Ciucci A; Zannoni GF; Buttarelli M; Martinelli E; Mascilini F; Petrillo M; Ferrandina G; Scambia G; Gallo D
Oncotarget; 2016 Oct; 7(42):68033-68043. PubMed ID: 27462782
[TBL] [Abstract][Full Text] [Related]
8. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer.
Edin S; Wikberg ML; Dahlin AM; Rutegård J; Öberg Å; Oldenborg PA; Palmqvist R
PLoS One; 2012; 7(10):e47045. PubMed ID: 23077543
[TBL] [Abstract][Full Text] [Related]
9. Macrophage-specific nanotechnology-driven CD163 overexpression in human macrophages results in an M2 phenotype under inflammatory conditions.
Alvarado-Vazquez PA; Bernal L; Paige CA; Grosick RL; Moracho Vilrriales C; Ferreira DW; Ulecia-Morón C; Romero-Sandoval EA
Immunobiology; 2017 Aug; 222(8-9):900-912. PubMed ID: 28545809
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Yuan X; Zhang J; Li D; Mao Y; Mo F; Du W; Ma X
Gynecol Oncol; 2017 Oct; 147(1):181-187. PubMed ID: 28698008
[TBL] [Abstract][Full Text] [Related]
11. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.
Ko SY; Ladanyi A; Lengyel E; Naora H
Am J Pathol; 2014 Jan; 184(1):271-81. PubMed ID: 24332016
[TBL] [Abstract][Full Text] [Related]
12. Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly.
Poles WA; Nishi EE; de Oliveira MB; Eugênio AIP; de Andrade TA; Campos AHFM; de Campos RR; Vassallo J; Alves AC; Scapulatempo Neto C; Paes RAP; Landman G; Zerbini MCN; Colleoni GWB
Cancer Immunol Immunother; 2019 Feb; 68(2):269-282. PubMed ID: 30430204
[TBL] [Abstract][Full Text] [Related]
13. Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release.
Sierra-Filardi E; Vega MA; Sánchez-Mateos P; Corbí AL; Puig-Kröger A
Immunobiology; 2010; 215(9-10):788-95. PubMed ID: 20580464
[TBL] [Abstract][Full Text] [Related]
14. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
[TBL] [Abstract][Full Text] [Related]
15. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.
Zhang M; He Y; Sun X; Li Q; Wang W; Zhao A; Di W
J Ovarian Res; 2014 Feb; 7():19. PubMed ID: 24507759
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.
Shabo I; Stål O; Olsson H; Doré S; Svanvik J
Int J Cancer; 2008 Aug; 123(4):780-6. PubMed ID: 18506688
[TBL] [Abstract][Full Text] [Related]
17. STAT3 is over-activated within CD163
Andersen MN; Andersen NF; Lauridsen KL; Etzerodt A; Sorensen BS; Abildgaard N; Plesner T; Hokland M; Møller HJ
Cancer Immunol Immunother; 2022 Jan; 71(1):177-187. PubMed ID: 34061243
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery.
Garvin S; Oda H; Arnesson LG; Lindström A; Shabo I
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1253-1263. PubMed ID: 29725763
[TBL] [Abstract][Full Text] [Related]
19. CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma.
He KF; Zhang L; Huang CF; Ma SR; Wang YF; Wang WM; Zhao ZL; Liu B; Zhao YF; Zhang WF; Sun ZJ
Biomed Res Int; 2014; 2014():838632. PubMed ID: 24883329
[TBL] [Abstract][Full Text] [Related]
20. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
